Johannes Atta

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Urban Scheuring, Patrick T. Bruck, Johannes Atta et al. · Blood · 2002 · 75 citations

Medicine, Hematology, Oncology +14

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

Urban Scheuring, Anja Binckebanck, Nicola Gökbuget et al. · Blood · 2003 · 50 citations · Full text

Medicine, Hematology, Oncology +11

Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients

Heiner Zimmermann, Petra Reinke, R. Neuhaus et al. · Cancer · 2012 · 36 citations · Full text

Medicine, Hematology, Oncology +12

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (<scp>GHSG</scp>) phase‐I trial

Boris Böll, Annette Plütschow, Carolin Bürkle et al. · British Journal of Haematology · 2018 · 25 citations

Medicine, Oncology, Pharmacotherapy +17

High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation

Gesine Bug, Johannes Atta, Stefan Klein et al. · Annals of Hematology · 2005 · 19 citations

Medicine, Hematology, Oncology +16